Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53

Blood

Volumn 109, Issue 6, 2007, Pages 2589-2596

  Irish, Jonathan M ^a   Ånensen, Nina ^b   Hovland, Randi ^b,c   Skavland, Jørn ^b   Børresen Dale, Anne Lise ^d   Bruserud, Øystein ^b,c   Nolan, Garry P ^a,e   Gjertsen, Bjørn T ^b,c  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN P53; PROTEIN P63; SERINE; STAT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DNA DAMAGE; FLOW CYTOMETRY; GENE DUPLICATION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 33947230787     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-004234     Document Type: Article

References (37)

1. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004;118:217-228.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
3. Irish JM, Kotecha N, Nolan GP. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer. 2006;6:146-155.
4. Fenaux P, Preudhomme C, Quiquandon I, et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol. 1992;80:178-183.
5. Schottelius A, Brennscheidt U, Ludwig WD, Mertelsmann RH, Herrmann F, Lubbert M. Mechanisms of p53 alteration in acute leukemias. Leukemia. 1994;8:1673-1681.
6. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
7. Zheng A, Castren K, Saily M, Savolainen ER, Koistinen P, Vahakangas K. p53 status of newly established acute myeloid leukaemia cell lines. Br J Cancer. 1999;79:407-415.
8. Somasundaram K. Tumor suppressor p53: regulation and function. Front Biosci. 2000;5:D424-437.
9. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 2001;268:2764-2772.
10. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ. 2003;10:400-403.
11. Del Principe MI, Del Poeta G, Venditti A, et al. Apoptosis and immaturity in acute myeloid leukemia. Hematology. 2005;10:25-34.
12. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091-3096.
13. Kornblau SM, Thall PF, Estrov Z, et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999;5:1758-1766.
14. Lauria F, Raspadori D, Rondelli D, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 1997;11:2075-2078.
15. Venditti A, Del Poeta G, Maurillo L, et al. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica. 2004;89:934-939.
16. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2003;101:2125-2131.
17. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene. 2000;19:2511-2522.
18. Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2001:62-86.
19. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood. 2003;101:2940-2954.
20. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
21. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica. 2003;88:416-428.
22. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658-3665.
23. Heiss E, Masson K, Sundberg C, et al. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood. 2006;108:1542-1550.
24. Rocnik JL, Okabe R, Yu JC, et al. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood. 2006;108:1339-1345.
25. Bruserud O, Gjertsen BT, von Volkman HL. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J Hematother Stem Cell Res. 2000;9:923-932.
26. Sorlie T, Johnsen H, Vu P, Lind GE, Lothe R, Borresen-Dale AL. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. Methods Mol Biol. 2005;291:207-216.
27. Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150-3159.
28. Matsuo Y, MacLeod RA, Uphoff CC, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia. 1997;11:1469-1477.
29. Karlsson R, Engstrom M, Jonsson M, et al. Phosphatidylinositol 3-kinase is essential for kit ligand-mediated survival, whereas interleukin-3 and flt3 ligand induce expression of antiapoptotic Bcl-2 family genes. J Leukoc Biol. 2003;74:923-931.
30. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res. 2006;12:3985-3992.
31. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-799.
32. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997;89:2959-2965.
33. Frost BM, Nygren P, Gustafsson G, et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;122:376-385.
34. Palle J, Frost BM, Forestier E, et al. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol. 2005;129:189-198.
35. Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood. 2000;96:2879-2886.
36. Norgaard JM, Langkjer ST, Palshof T, Pedersen B, Hokland P. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. Eur J Haematol. 2001;66:160-167.
37. Ryningen A, Ersvaer E, Oyan AM, et al. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res. 2006;30:1531-1540.